Novartis

CPDR001X2X01B

NCT04058756

JCP069

Rollover Study for Continued Safety and Tolerability in Subjects Treated with Spartalizumab Alone or in Combination With Other Study Treatments

Status:

Closed to Accrual

26459-200.png

I

Phase

Line of Therapy.png

Roll over

Line of Therapy

Disease Stage.png

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Spartalizumab

Treatment Arms

o Experimental: Spartalizumab